Full Product Name
CILP siRNA (Mouse)
Product Synonym Names
Cartilage intermediate layer protein 1; CILP-1
Product Gene Name
CILP sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q66K08
Specificity
CILP siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse CILP gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of CILP sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
CILP sirna
siRNA to inhibit CILP expression using RNA interference
Applications Tested/Suitable for CILP sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for CILP. It may not necessarily be applicable to this product.
NCBI Accession #
NP_775561.1
[Other Products]
NCBI GenBank Nucleotide #
NM_173385.2
[Other Products]
UniProt Primary Accession #
Q66K08
[Other Products]
UniProt Secondary Accession #
Q7TSS0; Q7TSS1; Q8BV01[Other Products]
UniProt Related Accession #
Q66K08[Other Products]
Molecular Weight
132,334 Da
NCBI Official Full Name
cartilage intermediate layer protein 1
NCBI Official Synonym Full Names
cartilage intermediate layer protein, nucleotide pyrophosphohydrolase
NCBI Official Symbol
Cilp??[Similar Products]
NCBI Official Synonym Symbols
9830114D16; C130036G17Rik
??[Similar Products]
NCBI Protein Information
cartilage intermediate layer protein 1
UniProt Protein Name
Cartilage intermediate layer protein 1
Protein Family
Cartilage intermediate layer protein
UniProt Gene Name
Cilp??[Similar Products]
UniProt Synonym Gene Names
CILP-1??[Similar Products]
UniProt Entry Name
CILP1_MOUSE
UniProt Comments for CILP
CILP: Probably plays a role in cartilage scaffolding. May act by antagonizing TGF-beta1 (TGFB1) and IGF1 functions. Has the ability to suppress IGF1-induced proliferation and sulfated proteoglycan synthesis, and inhibits ligand-induced IGF1R autophosphorylation. May inhibit TGFB1-mediated induction of cartilage matrix genes via its interaction with TGFB1. Overexpression may lead to impair chondrocyte growth and matrix repair and indirectly promote inorganic pyrophosphate (PPi) supersaturation in aging and osteoarthritis cartilage. Defects in CILP are a cause of susceptibility to intervertebral disk disease (IDD). A common musculo- skeletal disorder caused by degeneration of intervertebral disks of the lumbar spine. It results in low-back pain and unilateral leg pain. Susceptibility to intervertebral disk disease, is conferred by variant p.Ile395Thr (PubMed:15864306).
Protein type: Secreted; Motility/polarity/chemotaxis; Secreted, signal peptide
Cellular Component: extracellular matrix; proteinaceous extracellular matrix; extracellular space; extracellular region
Biological Process: negative regulation of insulin-like growth factor receptor signaling pathway
Research Articles on CILP
1. Overexpression of CILP in the nucleus pulposus cells promotes disc degeneration, indicating that CILP plays a direct role in the pathogenesis of lumbar disc disease.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
